In a seminal research study, Al-Hajj et al. identified BCSC by showing that 100 CD44+/CD24−/low-BC cells formed tumors in immune-deficient NOD/SCID mice, while even 100 times more cells of a different phenotype failed to do so. This evidence concerns the gene CD44 and breast cancer.